Stage IV Breast Cancer: Silvia's Patient Story

Patient Info: Silvia Litsching, Female, 60s | Stage IV

Metastatic Site: Bone | Liver

Silvia lived for many years with metastatic breast cancer involving bone and liver, receiving repeated systemic, radiation, liver-directed, bone-directed, complementary, and rehabilitation-based care while remaining active and positive.

Krankheitserfahrungen.deRead more →

Stage I Breast Cancer: Michelle's Survivor Story

Patient Info: Michelle Kang, Female, Under 40 | Stage I

Biomarkers: Hormone-positive breast cancer; no suspicious inherited genetic mutation reported

Michelle was 6 years cancer-free after Stage 1B hormone-positive breast cancer while continuing hormone therapy, Zometa, Signatera blood testing, reconstruction follow-up, and survivorship monitoring.

City of HopeRead more →

Stage IV HR-Positive Breast Cancer: Joelle's Patient Story

Patient Info: Joelle, Female, Under 40 | Stage IV

Biomarkers: HR-positive / hormone-positive

Metastatic Site: Bone/hip; lymph nodes; other sites not specified

Living with Stage IV hormone-positive breast cancer on ongoing systemic therapy and monitoring, with tumor-marker checks every 3 months and scans every 6 months; no remission or NED status is stated.

The Patient StoryRead more →

Stage II Triple-Negative Breast Cancer: Jennifer's Survivor Story

Patient Info: Jennifer Rancik, Female, Under 40 | Stage II

Biomarkers: BRCA1 mutation; triple-negative breast cancer

Jennifer entered remission in October 2017 after Stage II triple-negative breast cancer treatment and, as of October 2025, reported doing great and being off medications except occasional Zometa.

City of HopeRead more →

Stage IV ALK Lung Adenocarcinoma: Allison's Patient Story

Patient Info: Allison, Female, 40s | Stage IV

Biomarkers: ALK-positive fusion; later ALK resistance mutations reported

Metastatic Site: Bone (spine, femur, ribs, shoulder); brain

Allison was living with Stage IV ALK-positive lung cancer and had a strong response to targeted therapy: brain lesions cleared, most PET activity resolved, and the primary tumor shrank to about 1.5 cm. As of August 2025, she remained on second-line targeted therapy.

The Patient StoryRead more →

Breast Cancer: Marissa's Survivor Story

Patient Info: Marissa Coreno, Female, Under 40

Biomarkers: Tumor biomarkers not reported; no apparent genetic predisposition for breast cancer

As of August 2025, Marissa was 31, had no sign of cancer, and remained on estrogen-blocking therapy planned for 10 years after chemotherapy, bilateral mastectomies, reconstruction, radiation, a CDK 4/6 inhibitor pill and a bisphosphonate.

Cleveland ClinicRead more →

Breast cancer history: atypical pelvic fracture after long-term zoledronic acid

Patient Info: Anonymized, Female, 60s | Stage Metastatic/Advanced

Prior breast cancer treatment had been completed; CT during fracture evaluation showed no metastatic disease, and the atypical iliac wing fracture healed progressively with conservative care and teriparatide.

PubMed CentralRead more →

HR-positive HER2-negative metastatic breast cancer: bone metastases managed with sequential endocrine therapy

Patient Info: Anonymized, Female, 50s | Stage IV

Biomarkers: ER 90%+, PR 80%+, HER2-. CA 15-3 was tracked during treatment.

Metastatic Site: skull base; spine; sternum; ribs; left iliac bone;…

Metastatic HR-positive, HER2-negative breast cancer remained under active management; after earlier progression, palbociclib plus fulvestrant and zoledronic acid produced stable/remission findings on PET/CT at 3 months and again 1 year later, with continued 3-month follow-up recommended.

PubMed CentralRead more →

BRCA2-mutant metastatic breast cancer: complete response with rucaparib maintenance

Patient Info: Anonymized, Female, Under 40 | Stage IV

Biomarkers: Germline BRCA2 mutation; somatic BRCA2 mutation; HER2 amplification not seen by FISH; grade III IDC

Metastatic Site: bone

She maintained a complete response for 2 years on rucaparib, letrozole, and zoledronic acid after upfront metastatic BRCA2-mutated breast cancer involving bone, axillary nodes, and right-breast nodules.

PubMed CentralRead more →

Stage 4 lobular breast cancer: bone therapy switch to denosumab

Patient Info: Anonymized, Female, 40s | Stage IV

Biomarkers: Not reported for breast cancer; CRP 21 mg/dL and ESR 27 mm/hr were elevated during orbital inflammation workup

Metastatic Site: bone

As of April 2024, zoledronate-associated ocular inflammation resolved within 2.5 weeks, vision returned to 20/20 after about 3 weeks, and bone-support treatment was changed to denosumab; breast-cancer response was not reported.

PubMed CentralRead more →

Jeff

Patient Info: Jeff, Male | Stage IV

Biomarkers: EGFR exon 19 deletion

Metastatic Site: brain|bones|lymph nodes

The lung mass shrank, 5 brain lesions and the involved lymph node had no evidence of disease, and Jeff described his condition as stable while continuing osimertinib and bone-strengthening infusions.

Lung Cancer Research FoundationRead more →

Stage IV HER2-Positive Inflammatory Breast Cancer: Olivia's Survivor Story

Patient Info: Olivia Franz, Female, Under 40 | Stage IV

Biomarkers: HER2-positive

Metastatic Site: Bones; distant lymph nodes

As of October 2023, Olivia continued to show no evidence of disease on scans while receiving maintenance trastuzumab and pertuzumab every 3 weeks and zoledronic acid every 3 months for bone health.

MD AndersonRead more →

Metastatic breast cancer with a blood condition that mimicked multiple myeloma

Patient Info: Anonymized, Female | Stage IV

Biomarkers: Oestrogen receptor-positive

Metastatic Site: bone

Her pain came under control and the metastatic breast cancer remained stable for approximately 5 years. MGUS did not progress to myeloma, and she later died from causes unrelated to cancer.

PubMed CentralRead more →

Living with Stage 4 Lung Cancer (Plus Radiation & My Follow Up!) | Amy’s Story (3 of 3)

Patient Info: Amy, Female | Stage IV

Biomarkers: MET amplification

Metastatic Site: Bone/femur and hips; adrenal gland

As of July 2022, Amy was 3.5 years after Stage IV squamous cell lung cancer diagnosis, not NED but stable for about 3 years on Crizotinib with ongoing imaging and local treatment to lung/adrenal sites.

The Patient StoryRead more →

Stage IV MET Lung Squamous Cell Carcinoma: Amy's Patient Story

Patient Info: Amy, Female | Stage IV

Biomarkers: MET amplification

Metastatic Site: Bone/femur; lymph nodes; shoulder; adrenal glands;…

As of July 2022, Amy had a rapid and strong response to Crizotinib after MET amplification was found, with pain and lumps improving within about 2 weeks after Keytruda had failed.

The Patient StoryRead more →

Breast cancer recurrence presenting with numb chin syndrome

Patient Info: Anonymized, Female, 50s | Stage IV

Metastatic Site: sternum, left mandibular foramen

She was discharged ambulatory without lower-limb pain, although left mandibular numbness persisted, with monthly oncology follow-up planned.

PubMed CentralRead more →